Late intervention with the small molecule BB3 mitigates postischemic kidney injury

American Journal of Physiology - Renal Physiology

Volumn 311, Issue 2, 2016, Pages F352-F361

  Narayan, Prakash ^a   Duan, Bin ^a   Jiang, Kai ^a   Li, Jingsong ^a   Paka, Latha ^a   Yamin, Michael A ^a   Friedman, Scott L ^b   Weir, Matthew R ^c   Goldberg, Itzhak D ^a  

^a ANGION BIOMEDICA CORP   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Ischemia reperfusion; Kidney; Small molecule; Therapy

Indexed keywords

BB3; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTECTIVE AGENT; PROTEIN BCL 2; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; KIDNEY INJURY; KIDNEY ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENAL PROTECTION; REPERFUSION INJURY; SURVIVAL; TISSUE REGENERATION; UPREGULATION; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; ACUTE KIDNEY INJURY; ANIMAL; DRUG EFFECTS; KIDNEY TUBULE; METABOLISM; PATHOLOGY; REGENERATION; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; HEPATOCYTE GROWTH FACTOR; KIDNEY TUBULES; MALE; RATS; RATS, SPRAGUE-DAWLEY; REGENERATION; REPERFUSION INJURY;

EID: 84984597139     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00455.2015     Document Type: Article

References (49)

1. Adachi E, Hirose-Sugiura T, Kato Y, Ikebuchi F, Yamashita A, Abe T, Fukuta K, Adachi K, Matsumoto K. Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury. Pharmacology 94: 190–197, 2014.
2. Appasamy R, Tanabe M, Murase N, Zarnegar R, Venkataramanan R, Van Thiel DH, Michalopoulos GK. Hepatocyte growth factor, blood clearance, organ uptake, and biliary excretion in normal and partially hepatectomized rats. Lab Invest 68: 270–276, 1993.
3. Bellomo R, Auriemma S, Fabbri A, D’Onofrio A, Katz N, Mc-Cullough PA, Ricci Z, Shaw A, Ronco C. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int J Artif Organs 31: 166–178, 2000.
4. Chaparro RE, Izutsu M, Sasaki T, Sheng H, Zheng Y, Sadeghian H, Qin T, von Bornstadt D, Herisson F, Duan B, Li JS, Jiang K, Pearlstein M, Pearlstein RD, Smith DE, Goldberg ID, Ayata C, Warner DS. Sustained functional improvement by hepatocyte growth factor-like small molecule BB3 after focal cerebral ischemia in rats and mice. J Cereb Blood Flow Metab 35: 1044–1053, 2015.
5. Chintala MS, Jandhyala BS. Renal failure in haemorrhagic shock in dogs: salutary effects of the calcium entry blocker felodipine. Naunyn Schmiedebergs Arch Pharmacol 341: 357–363, 1990.
6. Choudhury D. Acute kidney injury: current perspectives. Postgrad Med 122: 29–40, 2010.
7. Cooper JE, Wiseman AC. Acute kidney injury in kidney transplantation. Curr Opin Nephrol Hypertens 22: 698–703, 2013.
8. da Silva CG, Maccariello ER, Wilson SW, Putheti P, Daniel S, Damrauer SM, Peterson CR, Siracuse JJ, Kaczmarek E, Ferran C. Hepatocyte growth factor preferentially activates the anti-inflammatory arm of NF-B signaling to induce A20 and protect renal proximal tubular epithelial cells from inflammation. J Cell Physiol 227: 1382–1390, 2012.
9. Dai C, Yang J, Liu Y. Single injection of naked plasmid encoding hepatocyte growth factor prevents cell death and ameliorates acute renal failure in mice. J Am Soc Nephrol 13: 411–422, 2002.
10. Dai C, Saleem MA, Holzman LB, Mathieson P, Liu Y. Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int 77: 962–973, 2010.
11. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med 4: 265–280, 2010.
12. Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr 23: 194–200, 2011.
13. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL). A new marker of kidney disease. Scand J Clin Lab Invest 241: 89–94, 2008.
14. Fiaschi-Taesch NM, Santos S, Reddy V, Van Why SK, Philbrick WF, Ortega A, Esbrit P, Orloff JJ, Garcia-Ocaña A. Prevention of acute ischemic renal failure by targeted delivery of growth factors to the proximal tubule in transgenic mice: the efficacy of parathyroid hormonerelated protein and hepatocyte growth factor. J Am Soc Nephrol 15: 112–125, 2004.
15. Furuichi K, Kaneko S, Wada T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 13: 9–14, 2009.
16. Gallagher SM, Jones DA, Kapur A, Wragg A, Harwood SM, Mathur R, Archbold RA, Uppal R, Yaqoob MM. Remote ischemic preconditioning has a neutral effect on the incidence of kidney injury after coronary artery bypass graft surgery. Kidney Int 87: 473–481, 2015.
17. Gao X, Mae H, Ayabe N, Takai T, Oshima K, Hattori M, Ueki T, Fujimoto J, Tanizawa T. Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int 62: 1238–1248, 2002.
18. Greenberg JH, Coca S, Parikh CR. Long-term risk of chronic kidney disease and mortality in children after acute kidney injury: a systematic review. BMC Nephrol 15: 184, 2014.
19. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62: 237–244, 2002.
20. Homsi E, Janino P, Biswas SK, Mizuno S, Nakamura T, Lopes de Faria JB. Attenuation of glycerol-induced acute kidney injury by previous partial hepatectomy: role of hepatocyte growth factor/c-met axis in tubular protection. Nephron Exp Nephrol 107: e95–e106, 2007.
21. BusinessWire. Angion Biomedica Corp. Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function (online). http://www.businesswire.com/news/home/201505-14005133/en/Angion-Biomedica-Corp.-Advances-BB3-Pivotal-Phase#.VYa0EizbLrc [22 June 2016].
22. ClinicalTrials.org. Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney (online). https://clinicaltrials.gov/ct2/show/NCT02474667?term_BB3&rank_2 [22 June 2016].
23. Wikipedia. Renal Function (online). https://en.wikipedia.org/wiki/Renal_function [22 June 2016].
24. PipelineReview.com. Angion Biomedica Corp. To Commence Phase 2 Clinical Trial of BB3 in Acute Kidney Injury (online). http://pipelinereview.com/index.php/2015060958040/Small-Molecules/Angion-Biomedica-Corp.-To-Commence-Phase-2-Clinical-Trial-of-BB3-in-Acute-Kidney-Injury.html [22 June 2016].
25. Isaka Y, Yamada K, Takabatake Y, Mizui M, Miura-Tsujie M, Ichimaru N, Yazawa K, Utsugi R, Okuyama A, Hori M, Imai E, Takahara S. Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther 12: 815–820, 2005.
26. Jiang WG, Hiscox S. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol Histopathol 12: 537–555, 1997.
27. Kamimoto M, Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. Biochem Biophys Res Commun 380: 333–337, 2009.
28. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci USA 91: 4357–4361, 1994.
29. Leung KC, Tonelli M, James MT. Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol 9: 77–85, 2013.
30. Linkermann A, De Zen F, Weinberg J, Kunzendorf U, Krautwald S. Programmed necrosis in acute kidney injury. Nephrol Dial Transplant 27: 3412–3419, 2012.
31. Liu Y, Tolbert EM, Lin L, Thursby MA, Sun AM, Nakamura T, Dworkin LD. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int 55: 442–453, 1999.
32. Mason S, Hader C, Marlier A, Moeckel G, Cantley LG. Met activation is required for early cytoprotection after ischemic kidney injury. J Am Soc Nephrol 201: 329–337, 2014.
33. Matsumoto K, Nakamura T. Roles of HGF as a pleiotropic factor in organ regeneration. EXS 65: 225–249, 1993.
34. McDonald MC, Mota-Filipe H, Paul A, Cuzzocrea S, Abdelrahman M, Harwood S, Plevin R, Chatterjee PK, Yaqoob MM, Thiemermann C. Calpain inhibitor I reduces the activation of nuclear factor-B and organ injury/dysfunction in hemorrhagic shock. FASEB J 15: 171–186, 2001.
35. Mizui M, Isaka Y, Takabatake Y, Mizuno S, Nakamura T, Ito T, Imai E, Hori M. Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int 65: 2041–2053, 2004.
36. Mou S, Wang Q, Shi B, Gu L, Ni Z. Hepatocyte growth factor ameliorates progression of interstitial injuries in tubular epithelial cells. Scand J Urol Nephrol 44: 121–128, 2010.
37. Nakatani T, Kim T, Uchida J, Kumata N, Kawashima H, Sugimura K. Hepatocyte growth factor ameliorates renal hemodynamic disorder after ischemia/reperfusion. Int J Mol Med 10: 217–219, 2002.
38. Ohnishi H, Mizuno S, Nakamura T. Inhibition of tubular cell proliferation by neutralizing endogenous HGF leads to renal hypoxia and bone marrow-derived cell engraftment in acute renal failure. Am J Physiol Renal Physiol 294: F326–F335, 2008.
39. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95: 2552–2558, 1997.
40. Ponticelli C. Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant 29: 1134–1140, 2014.
41. Rabkin R, Fervenza F, Tsao T, Sibley R, Friedlaender M, Hsu F, Lassman C, Hausmann M, Huie P, Schwall RH. Hepatocyte growth factor receptor in acute tubular necrosis. J Am Soc Nephrol 12: 531–540, 2001.
42. Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, Ito K, Sharma S, Ramadesikan S, Lee M, Briskin R, De Jager PL, Ngo TT, Radlinski M, Dear JW, Park KB, Betensky R, Krolewski AS, Bonventre JV. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 25: 2177–2186, 2014.
43. Speir RW, Stallings JD, Andrews JM, Gelnett MS, Brand TC, Salgar SK. Effects of valproic acid and dexamethasone administration on early bio-markers and gene expression profile in acute kidney ischemia-reperfusion injury in the rat. PLoS One 10: e0126622, 2015.
44. Versteilen AM, Di Maggio F, Leemreis JR, Groeneveld AB, Musters RJ, Sipkema P. Molecular mechanisms of acute renal failure following ischemia/reperfusion. Int J Artif Organs 27: 1019–1029, 2004.
45. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 121: 145–154, 1993.
46. Xing L, Muxun Z. Expression of c-met stimulated by high glucose in human renal tubular epithelial cells and its implication. J Huazhong Univ Sci Technolog Med Sci 27: 161–163, 2007.
47. Xing L, Cui R, Peng L, Ma J, Chen X, Xie RJ, Li B. Mesenchymal stem cells, not conditioned medium, contribute to kidney repair after ischemiareperfusion injury. Stem Cell Res Ther 5: 101, 2014.
48. Zhang J, Yang J, Liu Y. Role of Bcl-xL induction in HGF-mediated renal epithelial cell survival after oxidant stress. Int J Clin Exp Pathol 1: 242–253, 2008.
49. Zhou D, Tan RJ, Lin L, Zhou L, Liu Y. Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int 84: 509–520, 2013.